MAPT and Alzheimer disease: Growing evidence suggests that the effect of ApoE4 on AD risk is exerted through either the clearance inhibition or aggregation promotion of pathological tau as well as amyloid-beta3,10,11; however, the exact etiology of ApoE4 in AD remains elusive.